TNF and meningeal tuberculosis: A second strategy might be host-directed strategies to target immunopathology.1,29 Adjunctive aspirin is being evaluated in several trials.25 Tumor necrosis factor antagonist infliximab has benefit for tuberculous meningitis patients with corticosteroid-refractory inflammatory events later in the course of antituberculous treatment,30 but as deaths and irreversible neurological damage mostly occur in the first few weeks, trials should evaluate infliximab at treatment initiation.